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Abstract
The diagnostic–therapeutic pathways (DTPs) are emerging as useful instruments for clinical management of complex diseases 
as gastric cancer, whose treatment is challenging and requires a multidisciplinary approach. However, the DPTs of patients 
with gastric cancer are still not defined yet. The aim of this study was to define the optimal DPT to be applied for patients 
with gastric cancer in the Veneto region. Rather than defining the ideal DTPs a priori, we conducted a preliminary research 
by analyzing the differences in the actual DPTs for patients with gastric cancer among different hospitals (hub and spokes) in 
Veneto. Then, the final DPT was elaborated based on the current available best clinical evidences; however, also the areas of 
homogeneity among the actual DPTs of the included centers as well as the critical issues that had emerged by our preliminary 
analysis were taken into account for pathway design. High heterogeneity in actual DTPs of patients with gastric cancer was 
observed among the analyzed centres. Moreover, some of the major criticisms have been found at crucial points of the current 
pathways. Based on these data, a reference path that is applicable to the whole-regional health network was constructed. The 
reference DTP is focused on multidisciplinary team management of patients with gastric cancer. Clinical pathways are essential 
tools to properly manage complex diseases such as gastric cancer. As such, more efforts should be done to implement their use.
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Introduction
Despite the declining incidence, gastric cancer (GC) is still 
one of the leading causes of cancer death worldwide. Glob-
ally, in 2012, almost one million (952,000) of new cases 
were estimated, while the number of deaths due to GC was 
723,000 [1]. In Italy, in 2015, the total number of estimated 
new cases of GC was 13,987 [2]. In the same year, the num-
ber of gastric cancer-related deaths was 9247 [2]. The high 
lethality of GC reflects the complexity of the disease whose 
treatment is challenging and requires a multidisciplinary 
approach.
The diagnostic–therapeutic pathways (DTPs) are emerg-
ing as useful instruments for clinical management of com-
plex diseases. They are defined [3] as “structured multidisci-
plinary care plans that explicitly articulate the essential steps 
in treating specific clinical problems”. They basically allow 
the identification of all the activities of the patient’s pathway 
in a specific clinical scenario as well as the detection of 
critical steps of the process. Moreover, through the adop-
tion of quality indicators related to DTPs, healthcare per-
formances can be accurately gaged. The main aim of DTPs 
application is the homogenization of patient’s care process 
according to the best available clinical evidences. As such, 
DTPs are also essential instruments of new models of hub-
and-spoke networking in healthcare. Indeed, hub-and-spoke 
models distribute services delivery into a network consist-
ing of a core center (hub) that offers a full array of services, 
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complemented by secondary centers (spokes) that offer more 
limited sets of performances, centralizing those patients who 
need more intensive care to the hub for treatment [4]. In such 
kind of models, sharing DTPs among hub-and-spoke cent-
ers is fundamental as, on the one hand, DTPs clearly show 
which is the level of complexity needing patient’s routing to 
the hub; on the other hand, they set the appropriate areas for 
clinical intervention of satellite centers, making the whole 
system working more efficiently.
The DPTs of patients with gastric cancer are not com-
pletely analyzed and defined yet [5].
The aim of this study was to define the optimal DPT to be 
applied for patients with gastric cancer in the Veneto region. 
However, rather than defining the ideal DTPs a priori, we 
conducted a preliminary research by analyzing the differ-
ences in the actual DPTs for patients with gastric cancer 
among different hospitals (hub and spokes) in Veneto. Then, 
the final DPT was elaborated based on the current available 
best clinical evidences; however, also the areas of homogene-
ity among the actual DPTs of the included centers as well as 
the critical issues that had emerged by our preliminary analy-
sis were taken into account for pathway design. While the 
organizational findings have been previously discussed [6], 
in the present manuscript, we will report the clinical aspects 
of our research project on clinical pathways in GC care.
Methods
The centers involved in the project were all located in the 
Veneto region. Specifically, two hubs (the Verona University 
Hospital and the Veneto Institute of Oncology/Padova Uni-
versity Hospital) and three spokes (the Hospitals of Montec-
chio Maggiore and Arzignano, Venice City Hospital and the 
Rovigo City Hospital) were included. The study lasted for 
14 months (from November 2015 to December 2016). A steer-
ing committee composed by the researchers from the Institute 
of management of Scuola Superiore Sant’Anna of Pisa and 
Upper GI Surgery Division of Verona University was created. 
The methodology of the study was set by the research team 
from the Scuola Superiore Sant’Anna as previously reported 
[6]. First, a questionnaire was specifically developed with the 
aim of collecting data and detailed information on the organi-
zational and managerial arrangements to care patients with 
gastric cancer in each center. The questionnaire was divided 
in distinct sections exploring, respectively, the organizational 
characteristics of the center, the types and the numbers of 
treated patients, the modality of diagnostic phase, the adopted 
treatment strategies, and, finally, follow-up schedules.
Then, in each of the analyzed centers, a dedicated work-
ing group was constructed. This included surgeons, medi-
cal oncologists, radiation oncologists, endoscopists, gas-
troenterologists, radiologists, nuclear medicine physicians, 
pathologists, and nurses. Semi-structured interviews were 
conducted by the Scuola Superiore Sant’Anna Research team 
to each of the involved professionals though the administra-
tion of the above-mentioned questionnaire.
Based on the information collected during the interviews, 
the actual DTP of patients with gastric cancer in each center 
was mapped in the form of flowcharts. This allowed the rep-
resentation of the logical and the time sequence of all the 
activities. Moreover, the flowchart maps enabled the easy 
comparison among the current paths of all the analyzed cent-
ers. The DTPs map drafts were discussed and agreed in a 
plenary meeting at each center before the final version.
In the final phase of the study, based on the best available 
clinical evidences in the treatment of gastric cancer [7–10], 
the reference DTP was elaborated. Of course, the results of 
the current pathways analysis were taken in consideration 
when constructing the DTP. Specifically, information on the 
activities and services that are available at all the centres 
is used for the definition of the core of the reference DTP, 
while the critical issues emerged during the interviews were 
of help in pathway implementation.
Results
Comparative analysis of DTPs between the five 
centers
Differences in the actual DTPs are reported for each clinico-
organizational step as follows:
Diagnosis
The phase of diagnosis did not show significant differences 
between the five centers except for two points. First, the 
communication of pathological report of diagnostic gastric 
biopsies by the pathologist to the endoscopist or other physi-
cian who had required the upper GI endoscopy is not formal-
ized in all the centres.
In addition, the delivery of the histological report of 
diagnostic gastric biopsies to the patient differs among 
centers. Indeed, in one of the spoke centers, external 
patients usually pick up the result of the biopsies at the 
“Report Delivery Center “. Possible criticisms of this 
delivery modality are that the patient may forget to pick 
up and/or may be left alone while reading the diagnosis of 
gastric adenocarcinoma.
Staging
In all the centers, gastric cancer staging is performed 
through a thoraco-abdominal CT scan. Blood routine and 
tumor markers (CEA and CA19.9) examinations are always 
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taken. Only in case of not dirtied CT scan findings, the 
patient undergoes Magnetic Resonance and/or PET-CT. 
Unfortunately, a package of services including all the stag-
ing exams is not formalized in all the centres.
After clinical staging, a weekly multidisciplinary team 
(MDT) meeting, that is fundamental to choose the best ther-
apeutic option for each patient, is formalized only in two 
centers. In one spoke center, the cases are discussed at MDT 
after surgery. In all the centers, nutritionists and psycholo-
gists are not routinely involved in the MDT.
Treatment
This phase showed the most striking differences among 
centers. Only in the two hubs, the possibility to perform an 
endoscopic resection in case of clinical mucosal early gastric 
cancer ≤ 2 cm, without ulceration, with well differentiated, 
Laurèn intestinal histotype and with no clinical evidences of 
nodal metastases, is considered.
In one of the Spoke centers, neo-adjuvant chemotherapy 
is not usually performed in patients with locally advanced 
gastric cancer, because MDT discussion is done after 
surgery.
Surgical procedures showed no significant differences 
from the organizational and clinical point of views, while 
the number of surgically treated patients differed with the 
hubs treating more that 40 patients per year; conversely, the 
spokes does not exceed 20 cases.
With regard to indications and regimens of the first- and 
second-line chemotherapy for metastatic gastric cancer, 
there were no significant differences. Of note, relevant dif-
ferences exist for symptomatic metastatic patients in the 
chance to get simultaneous care. Indeed, only at one of the 
hubs, an outpatient service for simultaneous care is avail-
able. Moreover, difficulty in activating palliative home care 
was found in all centers.
Follow‑up
Only minor differences were observed in the follow-up 
schedules among the included centers.
Elaboration of reference DTP for the patient 
with gastric adenocarcinoma in the Veneto region
Figure 1 shows the reference pathway representing the ideal 
sequence of activities that must be followed by a patient 
with gastric cancer depending mainly on his tumor burden 
at the time of diagnosis. To solve the issues emerged by the 
analysis of the actual DTPs, specific solutions are reported 
as areas of implementations (Fig. 1). In detail, the refer-
ence pathway provides that if a gastric adenocarcinoma is 
diagnosed on endoscopic biopsies, there is a formalized 
communication of the diagnosis to the physician who 
requested the gastroscopy or alternatively to the endoscopist 
who has made the diagnostic endoscopy. Then, the profes-
sional who receive the pathological report have to commu-
nicate the diagnosis to the patient. In addition, it is desirable 
that who communicates the diagnosis would also plan an 
outpatient visit to let the patient access the path. Another 
fundamental point of the reference path is the multidisci-
plinar team (MTD) discussion that has to be formalized in 
each centre. MDT meeting should be taken soon after the 
completion of clinical staging to choose the best treatment 
option for each patient. MDT discussion is also needed after 
re-staging at the end of preoperative multimodal therapies 
as well as whenever there is the need of selecting among 
different treatment strategies (Fig. 1). Nutritionists and psy-
chologists should be included in the team.
With regard to the therapeutic steps, the path remarks 
the need of centralization in case of complex procedures 
requiring dedicated expert professionals as endoscopic sub-
mucosal dissection for the early gastric cancer (Fig. 1).
Finally, the care of metastatic patients should be improved 
by the activation of simultaneous care outpatient clinics to 
support symptomatic patients during palliative treatments. 
In addition, formalized and efficient process for the activa-
tion of Integrated Home Care Services has to be established.
Discussion
The DPTs of patients with gastric cancer are not completely 
analyzed and defined yet [5]. A recent survey showed that 
there are some differences in clinical paths for GC across ten 
European countries highlighting the need of harmonizing the 
care process for this cancer.
Our study showed that, also in Italy, at regional level, 
there is high heterogeneity in actual DTPs of patients with 
GC. Moreover, some of the major criticisms have been found 
at crucial points of the current pathways.
With the aim to standardize the management of patients 
in our region, we defined a reference DTP showing the ideal 
sequence of all the activities that should be followed in case 
of GC diagnosis in agreement with the best evidence-based 
data. Of note, the preliminary analysis on actual DTPs 
allowed the construction of a path that is applicable to the 
whole-regional network in which the clinical activities 
requiring centralization of patients to the hub are clearly 
identified.
Among the key elements of the reference path are the 
routine multidisciplinar team discussion and management 
of patients and the need of centralizing the patients to the 
hubs in case of challenging procedures as endoscopic resec-
tion for GC. In addition, a better global care of metastatic 
patients is provided.
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Sharing clinical pathways is fundamental to make health-
care networks working efficiently. Even if, in the present 
study, quality indicators have not been defined, the adoption 
of our reference path at regional level would also improve 
the assessment of health performances. Indeed, indicators 
specifically related to care process activities are easily iden-
tifiable and applicable to clinical practice.
In conclusion, clinical pathways are the best way to fol-
low the patient in his route from diagnosis to follow-up 
improving clinical outcomes and resources management. As 
such, DTPs are essential tools to properly manage complex 
diseases such as gastric cancer and more efforts should be 
done to implement their use.
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